Faustino R Pérez-López

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3736867/publications.pdf

Version: 2024-02-01

236 papers 6,407 citations

66343 42 h-index 106344 65 g-index

238 all docs

238 docs citations

times ranked

238

7814 citing authors

#	Article	IF	CITATIONS
1	Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility, 2015, 103, 1278-1288.e4.	1.0	234
2	Depressive disorders and the menopause transition. Maturitas, 2012, 71, 120-130.	2.4	172
3	Gender Differences in Cardiovascular Disease: Hormonal and Biochemical Influences. Reproductive Sciences, 2010, 17, 511-531.	2.5	155
4	Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas, 2009, 64, 67-79.	2.4	151
5	Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. Fertility and Sterility, 2009, 92, 1171-1186.	1.0	125
6	Insulin resistance and endometrial cancer risk: AÂsystematic review and meta-analysis. European Journal of Cancer, 2015, 51, 2747-2758.	2.8	122
7	Assessment of sexuality among middle-aged women using the Female Sexual Function Index. Climacteric, 2009, 12, 213-221.	2.4	116
8	Effect of exercise on sleep quality and insomnia in middle-aged women: A systematic review and meta-analysis of randomized controlled trials. Maturitas, 2017, 100, 49-56.	2.4	107
9	Firstâ€trimester maternal serum 25â€hydroxyvitamin D ₃ status and pregnancy outcome. International Journal of Gynecology and Obstetrics, 2012, 116, 6-9.	2.3	105
10	The Role of Vitamin D in Fertility and during Pregnancy and Lactation: A Review of Clinical Data. International Journal of Environmental Research and Public Health, 2018, 15, 2241.	2.6	101
11	Vitamin D: The secosteroid hormone and human reproduction. Gynecological Endocrinology, 2007, 23, 13-24.	1.7	97
12	EMAS position statement: Vitamin D and postmenopausal health. Maturitas, 2012, 71, 83-88.	2.4	95
13	Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101, 23-30.	2.4	94
14	Vitamin D and aging: Beyond calcium and bone metabolism. Maturitas, 2011, 69, 27-36.	2.4	85
15	EMAS position statement: Management of uterine fibroids. Maturitas, 2014, 79, 106-116.	2.4	85
16	Vitamin D and its implications for musculoskeletal health in women: An update. Maturitas, 2007, 58, 117-137.	2.4	84
17	Vitamin D testing: advantages and limits of the current assays. European Journal of Clinical Nutrition, 2020, 74, 231-247.	2.9	81
18	EMAS position statement: The ten point guide to the integral management of menopausal health. Maturitas, 2015, 81, 88-92.	2.4	76

#	Article	IF	CITATIONS
19	Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas, 2014, 79, 86-90.	2.4	75
20	Osteosarcopenic obesity and fall prevention strategies. Maturitas, 2015, 80, 126-132.	2.4	71
21	EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. Maturitas, 2015, 81, 410-413.	2.4	70
22	Assessment of sexual function and related factors in mid-aged sexually active Spanish women with the six-item Female Sex Function Index. Menopause, 2012, 19, 1224-1230.	2.0	68
23	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas, 2016, 89, 63-72.	2.4	67
24	Perceived stress, insomnia and related factors in women around the menopause. Maturitas, 2012, 72, 367-372.	2.4	66
25	Assessment of sexual function of mid-aged Ecuadorian women with the 6-item Female Sexual Function Index. Maturitas, 2012, 71, 407-412.	2.4	64
26	EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas, 2012, 73, 171-174.	2.4	63
27	Obesity is Related to Increased Menopausal Symptoms among Spanish Women. Menopause International, 2010, 16, 105-110.	1.6	62
28	Assessing predictors of sexual function in mid-aged sexually active women. Maturitas, 2011, 68, 387-390.	2.4	62
29	Coronavirus disease 2019 and gender-related mortality in European countries: A meta-analysis. Maturitas, 2020, 141, 59-62.	2.4	62
30	Factors related to insomnia and sleepiness in the late third trimester of pregnancy. Archives of Gynecology and Obstetrics, 2012, 286, 55-61.	1.7	61
31	Factors relating to insomnia during the menopausal transition as evaluated by the Insomnia Severity Index. Maturitas, 2011, 69, 157-161.	2.4	59
32	Lichen sclerosus in women: a review. Climacteric, 2017, 20, 339-347.	2.4	59
33	Effect of exercise alone or combined with dietary supplements on anthropometric and physical performance measures in community-dwelling elderly people with sarcopenic obesity: A meta-analysis of randomized controlled trials. Maturitas, 2018, 116, 24-35.	2.4	56
34	Sexual function, satisfaction with life and menopausal symptoms in middle-aged women. Maturitas, 2013, 75, 261-269.	2.4	55
35	Radioimmunoassay of Arginine Vasopressin in Rhesus Monkey Plasma. Endocrinology, 1976, 98, 975-981.	2.8	54
36	Effects of programmed exercise on depressive symptoms in midlife and older women: A meta-analysis of randomized controlled trials. Maturitas, 2017, 106, 38-47.	2.4	54

#	Article	IF	Citations
37	EMAS position statement: Testosterone replacement therapy in the aging male― Maturitas, 2016, 84, 94-99.	2.4	53
38	Severe menopausal symptoms in middle-aged women are associated to female and male factors. Archives of Gynecology and Obstetrics, 2010, 281, 879-885.	1.7	51
39	Depressive Symptoms and Resilience among Pregnant Adolescents: A Case-Control Study. Obstetrics and Gynecology International, 2010, 2010, 1-7.	1.3	47
40	EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women. Maturitas, 2013, 75, 181-190.	2.4	46
41	lodine and thyroid hormones during pregnancy and postpartum. Gynecological Endocrinology, 2007, 23, 414-428.	1.7	45
42	Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas, 2014, 77, 370-374.	2.4	45
43	Resilience, depressed mood, and menopausal symptoms in postmenopausal women. Menopause, 2014, 21, 159-164.	2.0	44
44	An evaluation of the contents and quality of menopause information on the World Wide Web. Maturitas, 2004, 49, 276-282.	2.4	42
45	Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas, 2009, 62, 248-262.	2.4	42
46	Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas, 2017, 95, 65-71.	2.4	42
47	Assessing the content and quality of information on the treatment of postmenopausal osteoporosis on the World Wide Web. Gynecological Endocrinology, 2006, 22, 669-675.	1.7	41
48	Sexual Function Assessment in Postmenopausal Women with the 14â€Item Changes in Sexual Functioning Questionnaire. Journal of Sexual Medicine, 2011, 8, 2144-2151.	0.6	41
49	Obesity-related insulin resistance in adolescents: a systematic review and meta-analysis of observational studies. Gynecological Endocrinology, 2017, 33, 179-184.	1.7	41
50	EMAS recommendations for conditions in the workplace for menopausal women. Maturitas, 2016, 85, 79-81.	2.4	40
51	Depressive symptoms in climacteric women are related to menopausal symptom intensity and partner factors. Climacteric, 2009, 12, 395-403.	2.4	39
52	Bone Mass Gain During Puberty and Adolescence: Deconstructing Gender Characteristics. Current Medicinal Chemistry, 2010, 17, 453-466.	2.4	39
53	Life satisfaction, loneliness and related factors during female midlife. Maturitas, 2012, 72, 88-92.	2.4	39
54	EMAS position statement: Diet and health in midlife and beyond. Maturitas, 2013, 74, 99-104.	2.4	39

#	Article	IF	Citations
55	Management of pudendal neuralgia. Climacteric, 2014, 17, 654-656.	2.4	39
56	Exercise alone or combined with dietary supplements for sarcopenic obesity in community-dwelling older people: A systematic review of randomized controlled trials. Maturitas, 2018, 110, 92-103.	2.4	39
57	First Trimester Serum 25-Hydroxyvitamin D Status and Factors Related to Lower Levels in Gravids Living in the Spanish Mediterranean Coast. Reproductive Sciences, 2011, 18, 730-736.	2.5	38
58	Soy isoflavones improve insulin sensitivity without changing serum leptin among postmenopausal women. Climacteric, 2012, 15, 611-620.	2.4	38
59	Sleep disturbance, obesity, physical fitness and quality of life in older women: EXERNET study group. Climacteric, 2017, 20, 72-79.	2.4	38
60	Association between sexual function and depression in sexually active, mid-aged, Peruvian women. Climacteric, 2011, 14, 654-660.	2.4	37
61	Nutrition and health during mid-life: searching for solutions and meeting challenges for the aging population. Climacteric, 2013, 16, 85-95.	2.4	36
62	<i>Vaccinium macrocarpon</i> : An interesting option for women with recurrent urinary tract infections and other health benefits. Journal of Obstetrics and Gynaecology Research, 2009, 35, 630-639.	1.3	35
63	Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus. Maturitas, 2017, 101, 6-11.	2.4	34
64	EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women. Maturitas, 2013, 74, 279-282.	2.4	33
65	Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 226-232.	1.5	33
66	Assessment of sleep quality and correlates in a large cohort of Colombian women around menopause. Menopause, 2013, 20, 464-469.	2.0	33
67	Effects of preeclampsia and eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2020, 102, 154012.	3.4	33
68	Assessment of subjective sleep disturbance and related factors during female mid-life with the Jenkins Sleep Scale. Maturitas, 2014, 77, 344-350.	2.4	32
69	Sexual Dysfunction Risk and Associated Factors in Young Peruvian University Women. Journal of Sexual Medicine, 2011, 8, 1701-1709.	0.6	30
70	Why sex matters: the biological mechanisms of cardiovascular disease. Gynecological Endocrinology, 2012, 28, 746-751.	1.7	30
71	Vitamin D supplementation during pregnancy: an overview. Current Opinion in Obstetrics and Gynecology, 2020, 32, 316-321.	2.0	30
72	The polycystic ovary syndrome and gynecological cancer risk. Gynecological Endocrinology, 2020, 36, 289-293.	1.7	30

#	Article	IF	Citations
73	Pro-inflammatory cytokine levels in postmenopausal women with the metabolic syndrome. Gynecological Endocrinology, 2011, 27, 685-691.	1.7	29
74	Postmenopausal osteoporosis and alendronate. Maturitas, 2004, 48, 179-192.	2.4	28
7 5	Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian cancer risk: A systematic review and meta-analysis. Maturitas, 2016, 94, 22-29.	2.4	28
76	Temporal Patterns of Vasopressin Release Following Electrical Stimulation of the Amygdala and the Neuroendocrine Pathway in the Monkey. Neuroendocrinology, 1977, 23, 61-75.	2.5	26
77	Effect of combined spinal–epidural analgesia versus epidural analgesia on labor and delivery duration. International Journal of Gynecology and Obstetrics, 2011, 114, 246-250.	2.3	26
78	Vitamin D Acquisition and Breast Cancer Risk. Reproductive Sciences, 2009, 16, 7-19.	2.5	25
79	Assessment of insomnia and related risk factors in postmenopausal women screened for the metabolic syndrome. Maturitas, 2013, 74, 154-159.	2.4	25
80	GONADOTROPHIN HORMONE RELEASING TESTS IN WOMEN RECEIVING HORMONAL CONTRACEPTION. Clinical Endocrinology, 1975, 4, 477-485.	2.4	24
81	<i>Cimicifuga racemosa</i> treatment and health related quality of life in post-menopausal Spanish women. Gynecological Endocrinology, 2009, 25, 21-26.	1.7	24
82	Factors related to increased daytime sleepiness during the menopausal transition as evaluated by the Epworth Sleepiness Scale. Maturitas, 2010, 65, 75-80.	2.4	24
83	Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. Gynecological Endocrinology, 2010, 26, 631-643.	1.7	24
84	Assessment of sexuality after hysterectomy using the Female Sexual Function Index. Journal of Obstetrics and Gynaecology, 2012, 32, 180-184.	0.9	24
85	Maternal serum cytokine levels in pregnancies complicated with threatened preterm labour. Gynecological Endocrinology, 2017, 33, 408-412.	1.7	24
86	The effect of endometriosis on sexual function as assessed with the Female Sexual Function Index: systematic review and meta-analysis. Gynecological Endocrinology, 2020, 36, 1015-1023.	1.7	24
87	A model of care for healthy menopause and ageing: EMAS position statement. Maturitas, 2016, 92, 1-6.	2.4	23
88	Metabolic syndrome during female midlife: what are the risks?. Climacteric, 2019, 22, 127-132.	2.4	23
89	Misoprostol combined with cervical single or double balloon catheters versus misoprostol alone for labor induction of singleton pregnancies: a meta-analysis of randomized trials. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 3453-3468.	1.5	23
90	Chagas disease in pregnancy: a non-endemic problem in a globalized world. Archives of Gynecology and Obstetrics, 2010, 282, 595-599.	1.7	22

#	Article	IF	CITATIONS
91	Iron and vitamin status biomarkers and its association with physical fitness in adolescents: the HELENA study. Journal of Applied Physiology, 2012, 113, 566-573.	2.5	22
92	Nitric oxide and pro-inflammatory cytokine serum levels in postmenopausal women with the metabolic syndrome. Gynecological Endocrinology, 2012, 28, 787-791.	1.7	22
93	Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. Maturitas, 2019, 129, 12-22.	2.4	22
94	Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease. Gynecological Endocrinology, 2021, 37, 746-752.	1.7	22
95	Polymorphisms of the methylenetetrahydrofolate reductase gene (C677T and A1298C) in nulliparous women complicated with preeclampsia. Gynecological Endocrinology, 2014, 30, 392-396.	1.7	21
96	Diagnosis and management of vulvodynia in postmenopausal women. Maturitas, 2018, 108, 84-94.	2.4	21
97	Assessment of self-esteem in mid-aged women. Maturitas, 2010, 66, 77-82.	2.4	20
98	Quality of life in a large cohort of mid-aged Colombian women assessed using the Cervantes Scale. Menopause, 2012, 19, 924-930.	2.0	20
99	EMAS position statement: Individualized breast cancer screening versus population-based mammography screening programmes. Maturitas, 2014, 79, 481-486.	2.4	20
100	Perinatal outcome in singleton pregnancies complicated with preeclampsia and eclampsia in Ecuador. Journal of Obstetrics and Gynaecology, 2016, 36, 581-584.	0.9	20
101	Vitamin D supplementation after the menopause. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093129.	3.2	20
102	Urinary incontinence, related factors and menopause-related quality of life in mid-aged women assessed with the Cervantes Scale. Maturitas, 2012, 73, 369-372.	2.4	19
103	Prevalence of insomnia and related factors in a large mid-aged female Colombian sample. Maturitas, 2013, 74, 346-351.	2.4	19
104	Assessment of menopause-related symptoms in mid-aged women with the 10-item Cervantes Scale. Maturitas, 2013, 76, 151-154.	2.4	19
105	Fall prevention in postmenopausal women: the role of Pilates exercise training. Climacteric, 2016, 19, 229-233.	2.4	19
106	Single versus double-balloon catheters for the induction of labor of singleton pregnancies: a meta-analysis of randomized and quasi-randomized controlled trials. Archives of Gynecology and Obstetrics, 2018, 297, 1089-1100.	1.7	19
107	Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecological Endocrinology, 2021, 37, 740-745.	1.7	19
108	Effect of programmed exercise on insulin sensitivity in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause, 2017, 24, 1404-1413.	2.0	18

#	Article	IF	CITATIONS
109	The effect of programmed exercise over anxiety symptoms in midlife and older women: a meta-analysis of randomized controlled trials. Climacteric, 2018, 21, 123-131.	2.4	18
110	Effectiveness of the cervical pessary for the prevention of preterm birth in singleton pregnancies with a short cervix: a meta-analysis of randomized trials. Archives of Gynecology and Obstetrics, 2019, 299, 1215-1231.	1.7	18
111	Association of female genital mutilation and female sexual dysfunction: A systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 254, 236-244.	1.1	18
112	Obstetric and perinatal outcomes of pregnancies with COVID 19: a systematic review and meta-analysis. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 9742-9758.	1.5	18
113	Associations between obesity, physical fitness, and urinary incontinence in non-institutionalized postmenopausal women: The elderly EXERNET multi-center study. Maturitas, 2015, 82, 208-214.	2.4	17
114	Resilience and related factors in urban, mid-aged Spanish women. Climacteric, 2015, 18, 867-872.	2.4	17
115	Assessing sexual problems in women at midlife using the short version of the female sexual function index. Maturitas, 2015, 82, 299-303.	2.4	17
116	Circulating kisspeptin and anti-müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 260, 85-98.	1.1	17
117	Risk of Development of Vulvar Cancer in Women With Lichen Sclerosus or Lichen Planus: A Systematic Review. Journal of Lower Genital Tract Disease, 2022, 26, 250-257.	1.9	17
118	Oestrogen and progesterone receptors in the human vagina during the menstrual cycle, pregnancy and postmenopause. Maturitas, 1993, 16, 139-144.	2.4	16
119	Hyperglycemia in postmenopausal women screened for the metabolic syndrome is associated to increased sexual complaints. Gynecological Endocrinology, 2010, 26, 86-92.	1.7	16
120	Resilience and related factors during female Ecuadorian mid-life. Maturitas, 2012, 72, 152-156.	2.4	16
121	Inhaled intrapartum analgesia using a 50–50Â% mixture of nitrous oxide–oxygen in a low-income hospital setting. Archives of Gynecology and Obstetrics, 2012, 286, 627-631.	1.7	16
122	The metabolic syndrome and its components in postmenopausal women. Gynecological Endocrinology, 2013, 29, 563-568.	1.7	16
123	Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement. Maturitas, 2017, 100, 86-91.	2.4	16
124	Pregnancy outcomes in younger and older adolescent mothers with severe preeclampsia. Adolescent Health, Medicine and Therapeutics, 2017, Volume 8, 81-86.	0.9	16
125	Uterine or paracervical lidocaine application for pain control during intrauterine contraceptive device insertion: a meta-analysis of randomised controlled trials. European Journal of Contraception and Reproductive Health Care, 2018, 23, 207-217.	1.5	16
126	Sunlight, the vitamin D endocrine system, and their relationships with gynaecologic cancer. Maturitas, 2008, 59, 101-113.	2.4	15

#	Article	IF	CITATIONS
127	First trimester serum levels of 25-hydroxyvitamin D, free \hat{I}^2 -human chorionic gonadotropin, and pregnancy-associated plasma protein A in Spanish women. Gynecological Endocrinology, 2011, 27, 1061-1064.	1.7	15
128	Assessment of follicular fluid leptin levels and insulin resistance asÂoutcome predictors in womenÂundergoing inÂvitro fertilization–intracytoplasmic sperm injection. Fertility and Sterility, 2014, 102, 1619-1625.	1.0	15
129	EMAS position statement: Fertility preservation. Maturitas, 2014, 77, 85-89.	2.4	15
130	Effect of programmed exercise on perceived stress in middle-aged and old women: A meta-analysis of randomized trials. Maturitas, 2018, 114, 1-8.	2.4	15
131	Uterine fibroids and preterm birth risk: A systematic review and metaâ€analysis. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1711-1727.	1.3	15
132	Studies on human prolactin physiology. Life Sciences, 1974, 15, 599-616.	4.3	14
133	Serum prolactin and thyrotrophin responses to thyrotrophin-releasing hormone at different times of the day in normal women. European Journal of Endocrinology, 1981, 97, 7-11.	3.7	14
134	Vitamin D and adolescent health. Adolescent Health, Medicine and Therapeutics, 2010, 1, 1.	0.9	14
135	Systematic review and meta-analysis regarding the association of endometriosis and preeclampsia in women conceiving spontaneously or through assisted reproductive technology. Pregnancy Hypertension, 2018, 14, 213-221.	1.4	14
136	Vitamin D, menopause, and aging: <i>quo vadis</i> ?. Climacteric, 2020, 23, 123-129.	2.4	14
137	Fragility fracture risk and skeletal muscle function. Climacteric, 2016, 19, 37-41.	2.4	13
138	Detection of Adverse Perinatal Outcomes at Term Delivery Using Ultrasound Estimated Percentile Weight at 35 Weeks of Gestation: Comparison of Five Fetal Growth Standards. Fetal Diagnosis and Therapy, 2020, 47, 104-114.	1.4	13
139	Clinical experiences with drospirenone: From reproductive to postmenopausal years. Maturitas, 2008, 60, 78-91.	2.4	12
140	Metabolic and hormonal parameters in post-menopausal women 10 years after transdermal oestradiol treatment, alone or combined to micronised oral progesterone. Gynecological Endocrinology, 2011, 27, 156-162.	1.7	12
141	Modification of the hand-held Vscan ultrasound and verification of its performance for transvaginal applications. Ultrasonics, 2013, 53, 17-22.	3.9	12
142	Assessment of obstructive sleep apnea-hypopnea syndrome risk at the end of pregnancy using the Berlin Questionnaire. Gynecological Endocrinology, 2015, 31, 715-719.	1.7	12
143	Evaluation of sexuality in a Paraguayan mid-aged female urban population using the six-item Female Sexual Function Index. Climacteric, 2016, 19, 256-260.	2.4	12
144	Evaluation of depressive symptoms in mid-aged women: report of a multicenter South American study. Menopause, 2017, 24, 1282-1288.	2.0	12

#	Article	IF	CITATIONS
145	Lower placental growth factor and higher free \hat{l}^2 -hCG and PAPP-A levels in the fetal circulation of near-term pregnancies complicated with severe preeclampsia. Gynecological Endocrinology, 2017, 33, 79-81.	1.7	12
146	Application of the 21-item Vulvovaginal Symptoms Questionnaire in postmenopausal Spanish women. Menopause, 2017, 24, 1295-1301.	2.0	12
147	Validation of the Six-item Female Sexual Function Index in Middle-Aged Brazilian Women. Revista Brasileira De Ginecologia E Obstetricia, 2019, 41, 432-439.	0.8	12
148	Perimenopause, body fat, metabolism and menopausal symptoms in relation to serum markers of adiposity, inflammation and digestive metabolism. Journal of Endocrinological Investigation, 2020, 43, 809-820.	3.3	12
149	Pituitary hormonal response to the orthopramides clebopride, bromopride, metoclopramide, and sulpiride. Fertility and Sterility, 1982, 37, 445-447.	1.0	11
150	Evaluation of the presence and severity of menopausal symptoms among postmenopausal women screened for the metabolic syndrome. Gynecological Endocrinology, 2014, 30, 918-924.	1.7	11
151	Erythrocyte folate content and serum folic acid and homocysteine levels in preeclamptic primigravidae teenagers living at high altitude. Archives of Gynecology and Obstetrics, 2013, 288, 1011-1015.	1.7	10
152	Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues. Climacteric, 2015, 18, 177-181.	2.4	10
153	Polymorphisms of the FTO and MTHFR genes and vascular, inflammatory and metabolic marker levels in postmenopausal women. Journal of Endocrinological Investigation, 2016, 39, 885-890.	3.3	10
154	Systematic review and meta-analysis of Spanish studies regarding the association between maternal 25-hydroxyvitamin D levels and perinatal outcomes. Gynecological Endocrinology, 2018, 34, 987-994.	1.7	10
155	Vaginal collagen I and III changes after carbon dioxide laser application in postmenopausal women with the genitourinary syndrome: a pilot study. Climacteric, 2022, 25, 186-194.	2.4	10
156	Pituitary responsiveness to gonadotropin-releasing hormone (GnRH) and thyrotropin-releasing hormone (TRH) during different phases of the same cycle of oral contraceptive steroid therapy. Fertility and Sterility, 1982, 37, 767-772.	1.0	9
157	Perceived control over menopausal hot flushes in mid-aged women. Gynecological Endocrinology, 2010, 26, 607-611.	1.7	9
158	Intimate partner violence and psychoemotional disturbance among pregnant women admitted to hospital with prenatal complications. International Journal of Gynecology and Obstetrics, 2012, 118, 194-197.	2.3	9
159	Leptin, vitamin D, and cardiorespiratory fitness as risk factors for insulin resistance in European adolescents: gender differences in the HELENA Study. Applied Physiology, Nutrition and Metabolism, 2014, 39, 530-537.	1.9	9
160	Application of the 10-item Cervantes Scale among mid-aged Ecuadorian women for the assessment of menopausal symptoms. Maturitas, 2014, 79, 100-105.	2.4	9
161	Factors related to muscle strength in postmenopausal women aged younger than 65 years with normal vitamin D status. Climacteric, 2019, 22, 390-394.	2.4	9
162	Menopausal symptoms are associated with non-adherence to highly active antiretroviral therapy in human immunodeficiency virus-infected middle-aged women. Climacteric, 2020, 23, 229-236.	2.4	9

#	Article	IF	CITATIONS
163	Association between depressed mood and sexual function among mid-aged Paraguayan women. Climacteric, 2020, 23, 566-573.	2.4	9
164	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 400-404.	1.1	9
165	Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing. Life Sciences, 2021, 271, 119200.	4.3	9
166	Maternal plasma and amniotic fluid coenzyme Q10 levels in preterm and term gestations: a pilot study. Archives of Gynecology and Obstetrics, 2011, 283, 67-71.	1.7	8
167	EMAS position statement: Late parenthood. Maturitas, 2013, 76, 200-204.	2.4	8
168	The severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection and the climacteric woman. Climacteric, 2020, 23, 525-527.	2.4	8
169	Lack of correlation between first trimester maternal serum 25-hydroxyvitamin D levels and ultrasound measured crown-rump length and nuchal translucency. Archives of Gynecology and Obstetrics, 2011, 284, 1585-1588.	1.7	7
170	Adipocytokines, Metabolic Syndrome, and Exercise. International Journal of Endocrinology, 2014, 2014, 1-3.	1.5	7
171	EMAS position statement: Menopause for medical students. Maturitas, 2014, 78, 67-69.	2.4	7
172	Increased mood symptoms in postmenopausal women related to the polymorphism rs743572 of the CYP17 A1 gene. Gynecological Endocrinology, 2016, 32, 827-830.	1.7	7
173	The effect of consuming milk and related products during human pregnancy over birth weight and perinatal outcomes: A systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 251, 235-245.	1.1	7
174	Handgrip strength, dynapenia, and related factors in postmenopausal women. Menopause, 2022, 29, 16-22.	2.0	7
175	Hormonal contraceptives and the risk of suicide: a systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 251, 28-35.	1.1	7
176	Etiopathogenesis of ovarian cancer. An inflamm-aging entity?. Gynecologic Oncology Reports, 2022, 42, 101018.	0.6	7
177	Beliefs regarding menopausal hot flushes among climacteric women as assessed with the Hot Flush Beliefs Scale. Maturitas, 2010, 66, 298-304.	2.4	6
178	Body mass index and its correlation to metabolic and hormone parameters in postmenopausal Spanish women. Gynecological Endocrinology, 2011, 27, 678-684.	1.7	6
179	EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture. Maturitas, 2014, 78, 131-137.	2.4	6
180	The Metabolic Syndrome in Mid-Aged Women. , 2017, , 141-158.		6

#	Article	lF	CITATIONS
181	Dynapenia and Sarcopenia During Female Midlife. , 2017, , 317-331.		6
182	Vulvodynia: A disease commonly hidden in plain sight. Case Reports in Women's Health, 2018, 20, e00079.	0.5	6
183	Assessing fatal cardiovascular disease risk with the SCORE (Systematic Coronary Risk Evaluation) scale in post-menopausal women 10 years after different hormone treatment regimens. Gynecological Endocrinology, 2010, 26, 533-538.	1.7	5
184	The B-Lynch technique for the management of intraoperative uterine atony. Journal of Obstetrics and Gynaecology, 2012, 32, 338-341.	0.9	5
185	Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future. Climacteric, 2016, 19, 417-418.	2.4	5
186	Umbilical cord plasma interferon-induced protein 10 (IP-10) and interferon-induced T-cell alpha chemoattractant (ITAC) levels are lower in women with severe preeclampsia. Journal of Perinatal Medicine, 2016, 44, 291-4.	1.4	5
187	Systematic review and meta-analysis of the effects of treatment modalities for vestibulodynia in women. European Journal of Contraception and Reproductive Health Care, 2019, 24, 337-346.	1.5	5
188	A cohort study of fetal growth in twin pregnancies by chorionicity: comparison with European and American standards. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 253, 238-248.	1.1	5
189	Preeclampsia and gestational hypertension are associated to low maternal circulating kisspeptin levels: a systematic review and meta-analysis. Gynecological Endocrinology, 2021, 37, 1055-1062.	1.7	5
190	Rethinking elective bilateral oophorectomy at the time of hysterectomy for benign disease. Maturitas, 2013, 76, 109-110.	2.4	4
191	Maternal serum 25-hydroxyvitamin D and C-reactive protein levels in pregnancies complicated with threatened preterm labour. Gynecological Endocrinology, 2016, 32, 777-781.	1.7	4
192	Validation of the 10-item Cervantes Scale in middle-aged Portuguese women: paper-and-pencil and online format assessment of menopause-related symptoms. Menopause, 2019, 26, 203-210.	2.0	4
193	Prediction of Large for Gestational Age by Ultrasound at 35 Weeks and Impact of Ultrasound-Delivery Interval: Comparison of 6 Standards. Fetal Diagnosis and Therapy, 2021, 48, 15-23.	1.4	4
194	Vitamin D, sunlight and longevity. Minerva Endocrinologica, 2011, 36, 257-66.	1.8	4
195	Metformin treatment and evolution of endometrial cancer. Climacteric, 2014, 17, 207-9.	2.4	4
196	Effect of prospidine administered at different times of the day on the development and growth of N-nitrosomethylurea-induced mammary tumors in Wistar ratsa~†. Cancer Letters, 1984, 24, 111-118.	7.2	3
197	Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast. Gynecological Endocrinology, 1993, 7, 185-189.	1.7	3
198	Low maternal vitamin D status during pregnancy requires appropriate therapeutic intervention. International Journal of Gynecology and Obstetrics, 2012, 116, 4-5.	2.3	3

#	Article	IF	CITATIONS
199	Menopausal hormone therapy and ovarian cancer: Putting risk into perspective. Maturitas, 2015, 81, 3-4.	2.4	3
200	Epirubicin dose and sequential hormonal therapyâ€"Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. European Journal of Cancer, 2016, 60, 146-153.	2.8	3
201	Polymorphism of the THOC5 of the transcription/export multiprotein complex and its correlation with the lipid and metabolic profile in middle-aged women. Gynecological Endocrinology, 2020, 36, 243-246.	1.7	3
202	Severe acute respiratory syndrome coronavirus 19 and human pregnancy. Gynecological Endocrinology, 2020, 36, 277-278.	1.7	3
203	Prediction of Late-Onset Small for Gestational Age and Fetal Growth Restriction by Fetal Biometry at 35 Weeks and Impact of Ultrasound–Delivery Interval: Comparison of Six Fetal Growth Standards. Journal of Clinical Medicine, 2021, 10, 2984.	2.4	3
204	Preeclampsia negatively affects future maternal metabolic and endocrine outcomes. Gynecological Endocrinology, 2021, 37, 773-774.	1.7	3
205	Stimulatory effect of clebopride on human prolactin secretion. Fertility and Sterility, 1980, 34, 452-5.	1.0	3
206	Vulvovaginal atrophy management with a laser: the placebo effect or the conditioning Pavlov reflex. Climacteric, 2022, 25, 323-326.	2.4	3
207	Prl, TSH, FSH, \hat{I}^2 -hCG and oestriol responses to repetitive (triple) LRH/TRH administration in the third trimester of human pregnancy. European Journal of Endocrinology, 1984, 106, 400-404.	3.7	2
208	Hypovitaminosis D during pregnancy: are we ready to recommend vitamin D supplementation?. Gynecological Endocrinology, 2012, 28, 856-858.	1.7	2
209	Maternal adropin levels in patients with gestational diabetes mellitus: a systematic review and meta-analysis. Gynecological Endocrinology, 2022, 38, 105-109.	1.7	2
210	Screening and Management of Female Sexual Dysfunction During the Second Half of Life. , 2019, , 165-185.		2
211	Leukocyte telomere length in women with and without polycystic ovary syndrome: a systematic review and meta-analysis. Gynecological Endocrinology, 2022, 38, 391-397.	1.7	2
212	Personalized Model to Predict Small for Gestational Age at Delivery Using Fetal Biometrics, Maternal Characteristics, and Pregnancy Biomarkers: A Retrospective Cohort Study of Births Assisted at a Spanish Hospital. Journal of Personalized Medicine, 2022, 12, 762.	2.5	2
213	Hormone therapy and the prevention of cardiovascular disease and cognitive decline: Where do we stand?. Maturitas, 2013, 74, 107-108.	2.4	1
214	Climacteric commentaries. Climacteric, 2014, 17, 308-316.	2.4	1
215	Effects of Exercise on Menopausal Prevalent Conditions. , 2019, , 467-484.		1
216	Sporadic Ovarian and Fallopian Tube Cancer in Postmenopausal Women., 2019,, 79-100.		1

#	Article	IF	CITATIONS
217	Effect of sulpiride on menopausal hot flashes: a randomized, double-blind, placebo-controlled clinical trial. Gynecological Endocrinology, 2020, 36, 247-251.	1.7	1
218	Association of breastfeeding duration with carotid intima-media thickness in later life: a systematic review and meta-analysis. Gynecological Endocrinology, 2021, 37, 778-784.	1.7	1
219	HUMAN PROLACTIN. European Journal of Endocrinology, 1975, 80, S156-S157.	3.7	1
220	Effect of metformin intervention on circulating irisin levels in polycystic ovary syndrome: a systematic review and collaborative meta-analysis. Gynecological Endocrinology, 2021, , 1-6.	1.7	1
221	Maternal serum irisin levels in normotensive and preeclamptic pregnancies: a systematic review and meta-analysis Â. Gynecological Endocrinology, 2022, , 1-8.	1.7	1
222	Low sexual function is associated with menopausal status in mid-aged women with human immunodeficiency virus infection. Menopause, 2022, Publish Ahead of Print, 317-326.	2.0	1
223	Adherence to osteoporosis medications. Climacteric, 2012, 15, 100-2.	2.4	1
224	Vitamin E supplementation improves testosterone, glucose- and lipid-related metabolism in women with polycystic ovary syndrome: a meta-analysis of randomized clinical trials. Gynecological Endocrinology, 0, , 1-10.	1.7	1
225	Female sexual function before and during the severe acute respiratory syndrome coronavirus-2 pandemic: a systematic review and Meta-analysis of longitudinal studies. Gynecological Endocrinology, 2022, 38, 632-638.	1.7	1
226	Tamoxifen and breast cancer. Gynecological Endocrinology, 1996, 10, 104-104.	1.7	0
227	Optimización del manejo de la mujer osteoporótica en la consulta de ginecologÃa. Progresos En Obstetricia Y Ginecologia, 2009, 52, 227-237.	0.0	0
228	Human Pregnancy and Parturition Clinical Management. Obstetrics and Gynecology International, 2010, 2010, 1-2.	1.3	0
229	Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study. Archives of Gynecology and Obstetrics, 2012, 285, 1183-1187.	1.7	O
230	Relationship between body composition, physical fitness and urinary incontinence in non-institutionalized postmenopausal women: the elderly EXERNET multicentre study. Maturitas, 2015, 81, 127.	2.4	0
231	Non-hormonal management of menopausal vasomotor symptoms: Psychosocial interventions. Maturitas, 2015, 82, 444-445.	2.4	0
232	Reply to the Letter to the Editor: A rebuttal: FSFI questionnaire does not assess female sexual function, by V. Puppo and G. Puppo. Maturitas, 2016, 83, 95-96.	2.4	0
233	Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al Maturitas, 2017, 102, 76-77.	2.4	0
234	The metabolic syndrome and diabetes are not synonymous. Climacteric, 2019, 22, 425-425.	2.4	0

#	Article	IF	CITATIONS
235	Conventional ovarian cancer screening does not reduce its related mortality in postmenopausal women. Climacteric, 2011, 14, 605-6.	2.4	0
236	Plasma homocysteine levels and handgrip strength in postmenopausal women. Climacteric, 2022, , 1-6.	2.4	0